Related Experiment Video
Updated: Jan 31, 2026

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure
Published on: November 29, 2018
GDF11 Decreases Pressure Overload-Induced Hypertrophy, but Can Cause Severe Cachexia and Premature Death
Shavonn C Harper1, Jaslyn Johnson1, Giulia Borghetti1
1From the Cardiovascular Research Center (S.C.H., J.J., G.B., T.W., M.W., H.K., E.A.F., Y.Y., Y.J., X.G., A.K.S., S.R.H.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
Insights
Growth differentiation factor 11 (GDF11) shows dose-dependent effects on the heart, reducing hypertrophy but causing severe weight loss and death at high doses. This highlights potential risks for GDF11 therapy.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Molecular Cardiology
Background:
- Growth differentiation factor 11 (GDF11) has shown potential benefits for heart health, including reversing age-related hypertrophy.
- However, conflicting reports suggest high GDF11 levels may cause muscle wasting, necessitating a clearer understanding of its dose-dependent effects.
Purpose of the Study:
- To investigate the dose-dependent effects of recombinant GDF11 (rGDF11) on normal and pressure overload-induced cardiac hypertrophy in mice.
Main Methods:
- Mice underwent transverse aortic constriction (TAC) surgery and were treated with varying doses of rGDF11 (0.5, 1.0, or 5.0 mg/kg).
- Cardiac hypertrophy, function, and fibrosis were assessed, alongside body and organ weights.
Main Results:
- GDF11 treatment reduced cardiac hypertrophy, improved cardiac function, and decreased fibrosis in a dose-dependent manner.
- However, the highest dose (5.0 mg/kg) led to severe body weight loss, cachexia, and mortality in both sham and TAC mice.
Conclusions:
- While GDF11 can mitigate pathological cardiac hypertrophy and fibrosis, its therapeutic use is limited by severe dose-dependent toxicity, including cachexia and death.
- High-dose GDF11 poses significant risks, potentially causing devastating effects on cardiac and other tissues.
Rationale:
Possible beneficial effects of GDF11 (growth differentiation factor 11) on the normal, diseased, and aging heart have been reported, including reversing aging-induced hypertrophy. These effects have not been well validated. High levels of GDF11 have also been shown to cause cardiac and skeletal muscle wasting. These controversies could be resolved if dose-dependent effects of GDF11 were defined in normal and aged animals as well as in pressure overload-induced pathological hypertrophy.
Objective:
To determine dose-dependent effects of GDF11 on normal hearts and those with pressure overload-induced cardiac hypertrophy.
Methods And Results:
Twelve- to 13-week-old C57BL/6 mice underwent transverse aortic constriction (TAC) surgery. One-week post-TAC, these mice received rGDF11 (recombinant GDF11) at 1 of 3 doses: 0.5, 1.0, or 5.0 mg/kg for up to 14 days. Treatment with GDF11 increased plasma concentrations of GDF11 and p-SMAD2 in the heart. There were no significant differences in the peak pressure gradients across the aortic constriction between treatment groups at 1 week post-TAC. Two weeks of GDF11 treatment caused dose-dependent decreases in cardiac hypertrophy as measured by heart weight/tibia length ratio, myocyte cross-sectional area, and left ventricular mass. GDF11 improved cardiac pump function while preventing TAC-induced ventricular dilation and caused a dose-dependent decrease in interstitial fibrosis (in vivo), despite increasing markers of fibroblast activation and myofibroblast transdifferentiation (in vitro). Treatment with the highest dose (5.0 mg/kg) of GDF11 caused severe body weight loss, with significant decreases in both muscle and organ weights and death in both sham and TAC mice.
Conclusions:
Although GDF11 treatment can reduce pathological cardiac hypertrophy and associated fibrosis while improving cardiac pump function in pressure overload, high doses of GDF11 cause severe cachexia and death. Use of GDF11 as a therapy could have potentially devastating actions on the heart and other tissues.
More Related Videos
10:18Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
09:24O-Ring Aortic Banding Versus Traditional Transverse Aortic Constriction for Modeling Pressure Overload-Induced Cardiac Hypertrophy
Published on: October 6, 2022
Related Concept Videos
Decreasing Function
Decreased Body Temperature
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Vapor Pressure Lowering
Vapor Pressure
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...